Dr. John Levine, MD

• Hematology & Oncology

• Pediatric Hematology & Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Memorial Sloan-kettering Cancer Center

  Fellowship Hospital

• Cornell University

  Fellowship Hospital, 1995

• Children's Hospital Los Angeles

  Residency Hospital, 1992

• Children's Hospital Los Angeles

  Internship Hospital, 1990

• Eastern Virginia Medical School

  Medical School, 1989

• Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia, 2018-09-06

• Therapeutic targets and emerging treatment options in gastrointestinal acute graft-versus-host disease, 2016-04-06

• Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials, 2018-01-08

• EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment, 2018-06-05

• Treosulfan, Fludarabine and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: A Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium, 2018-05-09

• BMT CTN State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20thYear, 2021-08-27

• Decoupling blood telomere length from age in recipients of allogeneic hematopoietic cell transplant in the BMT-CTN 1202, 2022-10-03

• Adolescent and Young Adult (AYA) versus Pediatric Patients with Acute Leukemia have a Significantly Increased Risk of Acute GVHD following Unrelated Donor (URD) Stem Cell Transplantation (SCT): The Children's Oncology Group Experience, 2022-01-06

• Priorities for Improving Outcomes for Non-Malignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network, 2020-02-05

• Evaluation of elafin as a prognostic biomarker in acute graft-versus-host disease, 2021-08-30

• Inefficiency of Two-Stage Designs in Phase II Oncology Clinical Trials with High Proportion of Inevaluable Patients, 2022-07-19

• Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease, 2018-11-03

• Disease Risk and GVHD Biomarkers Can Stratify Patients For Risk of Relapse and Non-Relapse Mortality Post Hematopoietic Cell Transplant, 2020-02-04

• Current and Emerging Targeted Therapies for Acute Graft versus Host Disease, 2020-11-21

• Infectious Risk Following Allogeneic Hematopoietic Cell Transplant Complicated by Acute Graft-Versus-Host Disease, 2016-12-22

• Monitoring Neurocognitive Functioning After Pediatric Cellular Therapy or Hematopoietic Cell Transplant: Guidelines From the COG Neurocognition in Cellular Therapies Task Force, 2022-07-21

• Microbial metabolite sensor GPR43 controls severity of experimental GVHD, 2018-09-10

• International, multi-center standardization of acute graft-versus-host disease clinical data collection: a report from the MAGIC consortium, 2015-09-16

• National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report, 2021-04-06

• Combination Therapy for GVHD Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial, 2015-11-06

• Obesity Induces Gut Microbiota Alterations and Augments Acute Graft-Versus-Host Disease After Allogeneic Stem Cell Transplantation, 2020-11-25

• Lessons Learned from Early Closure of a Clinical Trial for Steroid-Refractory Acute GVHD, 2021-11-23